Lethal C57BL/6 mouse model for Yezo virus infection and antiviral therapeutic evaluation Authors: Yu Liu, Ning Liu, Ge Zhang, Ziyan Liu, Tinglan Ji, Liang Li, Zedong Wang Published: 2026 ABSTRACT ABSTRACTYezo virus (YEZV) is an emerging tick-borne orthonairovirus that causes febrile illness and hepatic injury in humans. However, its pathogenesis and effective antiviral interventions remain poorly characterized. In this study, we generated a lethal, mouse-adapted YEZV strain through 30 serial passages in C57BL/6 mice. The adapted strain successfully recapitulated key clinical and pathological features of human YEZV infection, including leukopenia, thrombocytopenia, and hepatitis, as evidenced by elevated serum transaminases, high hepatic viral loads, and histopathological necroinflammatory lesions. Notably, female mice exhibited significantly higher mortality than males, revealing a sex-associated difference in disease susceptibility. Antiviral evaluation demonstrated that both favipiravir and ribavirin significantly suppressed in vivo YEZV replication, improved survival, and reduced hepatic viral burden. Collectively, this model establishes a rigorously validated platform for mechanistic studies of YEZV pathogenesis and the preclinical evaluation of antiviral therapeutics. Introduction Emerging tick-borne viruses have become a growing global public health concern in recent years, particularly tick-borne nairoviruses [1]. Crimean-Congo hemorrhagic fever virus (CCHFV) and Nairobi sheep disease virus are the two most representative tick-borne nairoviruses that cause disease in humans and animals in this genus [2,3]. In recent years, many emerging tick-borne orthonairoviruses associated with human febrile illness have been identified, such as Songling virus [4], Tacheng tick virus-1 [5], Yezo virus (YEZV) [6], Wetland virus [7], and Xuecheng virus [8], underscoring the complexity and pathogenic potential of this genus. As an important emerging tick-borne nairovirus, YEZV was first reported in 2021 in Japan among seven individuals with a history of tick exposure [6]. It has since been detected in tick-bitten patients in China and Russia [9,10]. Cases consistently present with mild clinical manifestations, including acute febrile illness, leukopenia, thrombocytopenia, and elevated hepatic enzyme levels [11–13]. Field surveillance has detected YEZV across multiple tick species, with Ixodes persulcatus recognized as the primary candidate vector [9,14,15]. Furthermore, serological surveys have revealed YEZV-specific antibodies in wild animals, including raccoons and tanukis [16]. Animal infection models showed that YEZV infection is asymptomatic in standard inbred mice but uniformly lethal in type I and II interferon receptor-deficient (AG129) mice [17]. Susceptible mice infected with YEZV exhibited elevated liver enzymes and pronounced histopathological lesions in the liver and spleen. Notably, favipiravir (T-705), a nucleoside antiviral that inhibits viral RNA polymerase, demonstrated strong anti-YEZV efficacy in this model [17,18]. Although ribavirin, a broad-spectrum guanosine analog [19], was not tested against YEZV in vivo here, it has established antiviral effects in mouse models of CCHFV [20], Severe fever with thrombocytopenia syndrome virus (SFTSV) [21], and Heartland bandavirus [22], albeit with lower potency than favipiravir. However, immunocompromised mice fail to mount physiologically relevant antiviral immune responses, rendering them unsuitable for dissecting virus–host interactions, pathogenesis, or immune-mediated protection. To address this limitation, we serially passaged YEZV in immunocompetent C57BL/6 mice for 30 generations, deriving a highly virulent variant that induces uniformly lethal infection. Materials and methods In vivo passage of YEZV in mice C57BL/6 mice were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The YEZV strain T-HLJ01 (GenBank accession numbers: ON563268–ON563270), previously described in our study [9], was isolated from the tick sample and propagated in Vero cells. The virus was inoculated intraperitoneally into a single 3-week-old male C57BL/6 mouse at a dose of 1 × 104 PFU (plaque-forming units). At 3 days post-infection (dpi), the mouse was humanely euthanized. Its liver was harvested, homogenized in 300 μL of sterile DMEM, and centrifuged at 12,000×g for 10 min (Eppendorf, Shanghai, China). The obtained passage 1 (P1) viral supernatant was then administered intraperitoneally to another 3-week-old C57BL/6 mouse. This serial passage procedure was repeated iteratively until the mice developed obvious clinical symptoms or succumbed to the infection by 3 dpi, at which point the passage process was terminated. The homogenized liver supernatants from P1 and the final passage viral strains were then isolated using Vero cells, titrated, and stored at −80 °C until use. Virus titration assay The T-HLJ01, P1, and P30 viral strains were quantified by plaque assay. Vero cells were counted using a hemocytometer (Bodboge, Guangzhou, China), and 1 × 104 cells were seeded into each well of a 24-well cell culture plate and incubated overnight. On the following day, the cells were washed with serum-free DMEM and inoculated with 250 μL of serial 10-fold virus dilutions (ranging from 10−1 to 10−8) prepared in serum-free DMEM. After adsorption at 37 °C for 2 h, the inoculum was removed and the cells were overlaid with 1 mL of a nutrient-agar mixture (1.6% agar in 2× DMEM, 1:1 v/v). Plates were inverted and incubated at 37 °C under 5% CO₂ for 7 days. The overlay was then gently aspirated, and monolayers were fixed with 250 µL of 4% paraformaldehyde for 1 h at room temperature and stained with 0.5% crystal violet. Plaques at each dilution were enumerated to calculate the PFU/mL, and the PFU/mL = (average number of plaques per well) / (volume of virus inoculum per well, in mL) × virus dilution factor. Experimental infection of mice with YEZV Three-week-old C57BL/6 mice (n = 6 per sex) were inoculated intraperitoneally with 1 × 10² or 1 × 10⁴ PFU of YEZV; DMEM served as the mock-infection control. Clinical signs were monitored twice daily, and body weight and survival status were recorded for 15 consecutive days. At 3, 7, and 15 dpi, three mice of each sex per group were humanely euthanized. Blood, throat swabs, anal swabs, and tissues, including the brain, heart, kidney, liver, spleen, lung, small intestine, and testis, were collected aseptically. Viral RNA copies in the collected samples were quantified by RT-qPCR. RNA extraction and RT-qPCR detection Viral RNA was extracted from tissue supernatants using the TIANamp Virus RNA Kit (TIANGEN, Beijing, China) and reverse-transcribed into cDNA using the PrimeScript™ RT Reagent Kit with gDNA Eraser (TaKaRa, Dalian, China), following the manufacturer’s instructions. Viral cDNA was quantified by RT-qPCR using the Premix Ex Taq™ (Probe qPCR) Kit (TaKaRa, Dalian, China), with primer and probe sequences provided in Table S1. Thermal cycling was performed as follows: initial denaturation at 95 °C for 30 s; followed by 50 cycles of denaturation at 95 °C for 5 s and annealing/extension at 60 °C for 30 s. Viral RNA copy numbers were calculated using a standard curve generated from tenfold serial dilutions of recombinant plasmids based on the formula: (copies)/μL = 10^ [(Ct value − 41.40) / −3.26] (Figure S1). Sample with a Ct value > 40 was considered as negative. Hematological and blood biochemical analyses Three male and three female C57BL/6 mice were inoculated intraperitoneally with 1 × 10⁴ PFU of YEZV. On 5 dpi, mice were humanely euthanized and collected for whole blood. Hematological parameters were quantified using an automated hematology analyzer. Concurrently, a comprehensive serum biochemical panel was performed. All clinical pathology analyses were conducted at the Veterinary Teaching Hospital of Jilin University. H&E staining and immunohistochemistry Formalin-fixed, paraffin-embedded liver and spleen tissues were sectioned at 3 µm thickness, deparaffinized, rehydrated, and subjected to heat-induced epitope retrieval. Sections were then processed for either hematoxylin–eosin (H&E) staining or immunohistochemistry (IHC). For H&E staining, sections were incubated with hematoxylin to stain nuclei, counterstained with eosin to visualize cytoplasmic and extracellular matrix components, dehydrated, cleared, and mounted. Morphological assessment was performed by light microscopy. For IHC, sections were incubated with a rabbit polyclonal antibody against the YEZV nucleocapsid (N) protein (1:200 dilution), raised in rabbits immunized with recombinant YEZV N protein. Detection was performed using the Ready-to-Use Fast Immunohistochemistry MaxVision™ HRP Kit (Maixin, Fuzhou, China), followed by 3, 3′-diaminobenzidine (DAB) chromogenic substrate. In vivo antiviral assay Favipiravir and ribavirin were purchased from RHAWN (Shanghai, China) and suspended in 0.5% (w/v) methylcellulose for oral administration. Female C57BL/6 mice (n = 6) were inoculated intraperitoneally with 1 × 10⁴ PFU of YEZV. Antiviral treatment was initiated at three different time points: 0 dpi (2 h post-infection), 1 dpi, or 3 dpi. For each time point, the treatment was given once daily by oral gavage for 7 consecutive days, at a dose of either 100 mg/kg/day or 300 mg/kg/day; the vehicle control group received an equivalent volume of 0.5% methylcellulose. All mice were monitored for 15 days to assess survival and body weight changes. Statistical analysis Data were analyzed using GraphPad Prism 9.5 (GraphPad Software, San Diego, CA, USA). Statistical comparisons between two independent groups were performed using the one-way ANOVA test or two-way ANOVA (or mixed model) test. Data are presented as mean ± standard deviation (SD). A two-sided p-value < 0.05 was considered statistically significant. Significance levels are indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, **** p < 0.0001. Results Clinical and viral dynamics of in vivo YEZV passage Serial passage of the T-HLJ01 strain in C57BL/6 mice induced a progressive intensification of clinical signs. While the initial passage (P1) caused only mild weight loss, subsequent passages triggered reduced activity, lethargy, and piloerection, culminating in a moribund state by P30 (Table S2). Except in the blood and testes, where viral copy numbers remained stable, viral titres in other tissues paralleled symptom severity, increasing progressively across passages. Notably, liver viral loads were consistently higher than those in all other evaluated tissues from P1 to P30 (Figure S2). Infection of mice with P1 and P30 YEZV strains To assess the pathogenicity of P1 and P30 YEZV strains in C57BL/6 mice, animals were intraperitoneally inoculated with 1 × 10² and 1 × 10⁴ PFU of each strain. For the P1 strain, all mice survived without overt clinical signs (Figure 1A). Only female mice exhibited transient weight loss, reaching a nadir at 4 dpi (1 × 10² PFU) and 6 dpi (1 × 10⁴ PFU), followed by full recovery. Male mice maintained stable weights until 9 dpi and subsequently gained weight progressively (Figure 1B). Figure 1.Survival and body weight changes of C57BL/6 mice infected with YEZV P1 and P30 strains. Three-week-old C57BL/6 mice (n = 6 per sex) were intraperitoneally inoculated with 1 × 10⁴ PFU of YEZV P1 (A, B) or P30 (C, D). Survival rates (A, C) and relative body weight changes (mean ± SD) (B, D) were monitored over 15 days post-infection. Statistical analyses were performed using two-way ANOVA test of GraphPad Prism 9.5. ns: p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.Four line graphs comparing survival and body weight of C57BL/6 mice given YEZV P1 or P30, showing stable P1 and reduced P30 outcomes.The figure shows four line graphs labeled A, B, C, and D that summarize survival and body weight of C57BL/6 mice after intraperitoneal infection with YEZV P1 or YEZV P30. All graphs use days post infection on the horizontal axis with a range from 0 to 15 and regular tick marks at 1 day intervals. In graph A, survival percentage is on the vertical axis from 0 to 100 with 20 unit tick intervals. All plotted lines stay at 100 survival for 15 days. In graph B, body weight percentage is on the vertical axis from 60 to 180 with 20 unit tick intervals. Separate lines show male and female mice given control medium or YEZV P1 at 1 times 10 to the power of 2 or 1 times 10 to the power of 4 plaque forming units. Control lines rise steadily to about 160 to 180, while infected groups cluster around 90 to 130, with females at 1 times 10 to the power of 4 plaque forming units dipping before recovering. In graph C, survival percentage again ranges from 0 to 100. Lines for YEZV P30 infected groups drop between 3 and 10 days to different final levels, with some reaching 0, and significance markers including ns, a single *, and a double * appear near separation points. In graph D, body weight percentage ranges from 60 to 180. Control mice show a steady gain toward about 170, whereas YEZV P30 infected groups initially lose weight to about 70 to 90 and then partly recover. All data are approximate. Survival and body weight changes of C57BL/6 mice infected with YEZV P1 and P30 strains. Three-week-old C57BL/6 mice (n = 6 per sex) were intraperitoneally inoculated with 1 × 10⁴ PFU of YEZV P1 (A, B) or P30 (C, D). Survival rates (A, C) and relative body weight changes (mean ± SD) (B, D) were monitored over 15 days post-infection. Statistical analyses were performed using two-way ANOVA test of GraphPad Prism 9.5. ns: p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. In contrast, all mice infected with the P30 strain developed clinical signs, such as piloerection and lethargy, by 3 dpi, with surviving animals beginning to recover between 8 and 10 dpi. All female mice infected with 1 × 10⁴ PFU succumbed to the infection between 6 and 7 dpi, whereas male mice infected at the same dose exhibited a 15-day survival rate of 50%. At the lower dose (1 × 10² PFU), the 15-day survival rates were 33.3% for females and 66.7% for males (Figure 1C). All infected mice experienced progressive weight loss starting at 2 dpi, reaching nadir body weights between 5 and 9 dpi (Figure 1D). They showed significantly reduced weight gain relative to controls. Weight changes showed no significant differences between doses or sexes, barring isolated time points (Table S3). Viral loads in P1- and P30-infected mice Mice were intraperitoneally inoculated with 1 × 10⁴ PFU of the P1 or P30 YEZV strain. Three male and three female mice were euthanized at 3, 7, and 15 dpi. For the P1 strain, viral RNA was detected in the blood and all examined tissues of both sexes at 3 dpi, with the liver showing the highest viral load (∼106 copies/mg). At 7 dpi, viral RNA was detectable only in the liver and spleen of both sexes, and it became undetectable across all tissues by 15 dpi (Figure 2A). Notably, daily throat and anal swabs collected from 1 to 15 dpi tested consistently negative for viral RNA in both sexes. Figure 2.YEZV P1 and P30 replication in blood and tissues of C57BL/6 mice. Three-week-old C57BL/6 mice (n = 3 per sex) were inoculated intraperitoneally with 1 × 10⁴ PFU of YEZV P1 (A) and P30 (B) and sacrificed at 3, 7, and 15 dpi for tissue and blood collection. Viral RNA copies were quantified by RT-qPCR. The dashed line indicates the LOD (limit of detection). The statistical analyses were performed using the two-way ANOVA test of GraphPad Prism 9.5. ns: p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.18 bar charts comparing YEZV P1 and P30 viral RNA levels in mouse tissues and blood over 3, 7, and 15 days after infection by sex.The figure shows 2 sets of bar charts labeled A and B for YEZV P1 and YEZV P30 strains. Each set contains 9 small charts arranged in a grid for heart, liver, spleen, lung, kidney, intestine, brain, testicle, and blood. Bars represent female and male C57BL slash 6 mice at 3, 7, and 15 days after intraperitoneal inoculation. The horizontal axis of each chart is labeled days after infection with virus at 3, 7, and 15. The vertical axis is labeled base 10 logarithm RNA copies per milligram for tissues or per milliliter for blood, ranging from 0 to 12 in steps of 4. Each bar has a dot indicating individual values, and a dashed horizontal line marks the detection threshold. Brackets with labels ns, asterisk, double asterisk, triple asterisk, or quadruple asterisk appear above some 3 and 7 day comparisons, indicating different p value categories. In the P1 charts, viral RNA is visible in blood and all tissues at 3 days, most prominently in liver, then mostly limited to liver and spleen at 7 days, and near or below the detection line at 15 days. In the P30 charts, bars at 3 and 7 days are higher across organs than in P1, especially in liver, spleen, lung, kidney, intestine, and blood, with values declining toward the detection line by 15 days. All data are approximate. YEZV P1 and P30 replication in blood and tissues of C57BL/6 mice. Three-week-old C57BL/6 mice (n = 3 per sex) were inoculated intraperitoneally with 1 × 10⁴ PFU of YEZV P1 (A) and P30 (B) and sacrificed at 3, 7, and 15 dpi for tissue and blood collection. Viral RNA copies were quantified by RT-qPCR. The dashed line indicates the LOD (limit of detection). The statistical analyses were performed using the two-way ANOVA test of GraphPad Prism 9.5. ns: p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. For the P30 strain, viral RNA was detected in the blood and all tissues (except the brain and testes) of male mice at 3 dpi. By 7 dpi, it disseminated to all tissues and blood, peaking in the liver. Viral RNA persisted in the livers of surviving males at 15 dpi. In females, viral RNA was detected in the blood and all tissues at both 3 and 7 dpi, with copy numbers significantly higher than those in males at corresponding time points (Figure 2B). Due to 100% mortality prior to 15 dpi, no samples were available for female mice at this time point. Similar to the P1 group, daily throat and anal swabs from P30-infected mice of both sexes consistently tested negative for viral RNA throughout the 15-day monitoring period. Histopathological and laboratory findings of mice with P30 YEZV Based on preceding infection kinetics and to highlight the pathological features in tissues prior to death, liver and spleen samples from male and female mice at 5 dpi were chosen for analysis. Morphologically, the livers and spleens of infected female mice were enlarged compared to those of the control group, with the livers exhibiting a noticeable whitish discoloration (Figure 3). In contrast, no such macroscopic alterations were observed in male mice. Figure 3.Pathological images of the liver and spleen after YEZV P30 infection. C57BL/6 mice (n = 3 per sex) were inoculated intraperitoneally with 1 × 10⁴ PFU of YEZV P30. At 5 dpi, mice were euthanized, and the livers and spleens were collected and fixed in 4% paraformaldehyde for H&E and IHC staining.Two grids of liver and spleen micrographs showing YEZV P30 mock, male 5 dpi, and enlarged female 5 dpi organs with H[amp]E and IHC stains. Pathological images of the liver and spleen after YEZV P30 infection. C57BL/6 mice (n = 3 per sex) were inoculated intraperitoneally with 1 × 10⁴ PFU of YEZV P30. At 5 dpi, mice were euthanized, and the livers and spleens were collected and fixed in 4% paraformaldehyde for H&E and IHC staining. Histopathological analysis revealed multifocal inflammatory cell infiltration within the hepatic parenchyma, accompanied by hepatocellular necrosis, in the livers of female mice (Figure 3A). Similar, albeit milder, lesions were observed in male mice. In the spleen, female mice exhibited a disruption of white pulp architecture and lymphoid depletion, whereas male mice displayed only mild changes (Figure 3B). Immunohistochemistry detected the YEZV antigen in both liver and spleen tissues, with female mice showing significantly more positive-staining areas than males (Figure 3). Complete blood count and serum biochemical analyses of blood collected at 5 dpi revealed significant leukopenia in both sexes, thrombocytopenia exclusively in females, and neutrophilia exclusively in males (Figure S3). Both sexes exhibited marked elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Additionally, total protein, albumin, and globulin levels were significantly reduced in both males and females (Figure S3). Validation of anti-YEZV effects of favipiravir and ribavirin in mice Building upon the preceding results, an intraperitoneal challenge of C57BL/6 female mice with 1 × 10⁴ PFU of YEZV was established as a lethal infection model for anti-viral evaluations. Given that favipiravir and ribavirin demonstrated antiviral activity against YEZV in a lethal AG129 mouse model in a previous study [17], we investigated the therapeutic efficacy of these two compounds in the current study. All mice in the favipiravir and ribavirin treatment groups administered at 300 mg/kg/day (initiated at 0, 1, or 3 dpi) survived the YEZV infection, with transient body weight loss, reaching a nadir at 6 dpi (Figure 4). In the groups receiving 100 mg/kg/day, 100% survival was achieved when treatment was initiated at 0 dpi. For treatments initiated at 1 or 3 dpi, favipiravir conferred a 15-day survival rate of 83.3%, whereas ribavirin yielded 15-day survival rates of 83.3% and 50.0%, respectively (Figure 4A, C). Furthermore, mice treated with 100 mg/kg/day of either drug exhibited slower body weight recovery compared with those receiving the 300 mg/kg/day dosage. All vehicle-treated control mice succumbed to YEZV infection by 7 dpi (Figure 4B, D). Figure 4.Antiviral efficacy of favipiravir and ribavirin against YEZV P30 infection in female C57BL/6 mice. Favipiravir and ribavirin were suspended in 0.5% (w/v) methylcellulose for oral gavage. Female C57BL/6 mice (n = 6 per group) were inoculated intraperitoneally with 1 × 10⁴ PFU of YEZV passage 30. Antiviral treatment was initiated at 0, 1, or 3 dpi and administered once daily by oral gavage for 7 consecutive days at 100 mg/kg or 300 mg/kg; vehicle controls received an equivalent volume of 0.5% methylcellulose. Mice were monitored for 15 days to assess survival (A: favipiravir; C: ribavirin) and relative body weight change (B: favipiravir; D: ribavirin).Four line graphs showing survival and body weight in YEZV P30 infected C57BL/6 mice treated with favipiravir or ribavirin over 15 days.The figure shows four line graphs summarizing outcomes in female C57BL/6 mice infected with Yezo virus passage 30 and treated with favipiravir or ribavirin. The upper left survival graph for favipiravir has the horizontal axis labeled days post infection, from 0 to 15 at 5 day intervals, and the vertical axis labeled survival percent, from 0 to 100 at 20 percent intervals. Curves show that all mice receiving 300 milligrams per kilogram per day starting at 0, 1, or 3 days post infection remain at 100 percent survival for 15 days, whereas the vehicle curve drops to 0 percent by 7 days and the 100 milligrams per kilogram per day curves decline partially by 15 days. The upper right body weight graph for favipiravir has the horizontal axis labeled days post infection, 0 to 15, and the vertical axis labeled body weight percent, 60 to 160, both with 1 to 2 unit tick marks. Lines for all treatment groups dip to about 80 percent around day 6 then gradually rise above 100 percent by day 15, with higher dose groups recovering faster. The lower left survival graph for ribavirin uses the same axes and scales, with complete survival for all 300 milligrams per kilogram per day groups, partial survival in 100 milligrams per kilogram per day groups started at 1 or 3 days, and 0 percent survival in vehicle by 7 days. The lower right body weight graph for ribavirin mirrors the favipiravir body weight pattern, with all groups showing a midcourse decrease followed by recovery, slower at 100 milligrams per kilogram per day. Legends list vehicle and each dosage and start day condition. All data are approximate. Antiviral efficacy of favipiravir and ribavirin against YEZV P30 infection in female C57BL/6 mice. Favipiravir and ribavirin were suspended in 0.5% (w/v) methylcellulose for oral gavage. Female C57BL/6 mice (n = 6 per group) were inoculated intraperitoneally with 1 × 10⁴ PFU of YEZV passage 30. Antiviral treatment was initiated at 0, 1, or 3 dpi and administered once daily by oral gavage for 7 consecutive days at 100 mg/kg or 300 mg/kg; vehicle controls received an equivalent volume of 0.5% methylcellulose. Mice were monitored for 15 days to assess survival (A: favipiravir; C: ribavirin) and relative body weight change (B: favipiravir; D: ribavirin). Viral loads in antiviral-treated mice To assess the in vivo antiviral efficacy of favipiravir and ribavirin, female C57BL/6 mice infected with 1 × 10⁴ PFU of YEZV received treatment at 300 mg/kg/day starting at 0 dpi. Subsets of mice (n = 3) were euthanized at 3, 7, and 15 dpi for tissue and blood collection to quantify viral loads. Following treatment with favipiravir or ribavirin, viral copy numbers in the blood and tissues of mice progressively decreased over the treatment duration and were significantly lower than those in the vehicle-treated control group. By 15 dpi, viral RNA was undetectable in the blood and most tissues, except for low copy numbers detected in the liver and spleen of a few individual mice. Notably, at 3 and 7 dpi in the liver and at 7 dpi in the spleen, viral copy numbers in the favipiravir-treated group were significantly lower than those in the ribavirin-treated group (Figure 5). Figure 5.Antiviral effects on viral replication in vivo. Female C57BL/6 mice (n = 3 per group) were inoculated intraperitoneally with 1 × 104 PFU of YEZV P30 and treated orally with 300 mg/kg favipiravir or Ribavirin, initiated at 0 dpi and administered once daily for 5 days. At 3,7 and 15 dpi, mice were euthanized and blood and tissues were collected. Viral RNA copies were quantified by RT-qPCR. The dashed line indicates the LOD. The statistical analyses were performed using the two-way ANOVA test of GraphPad Prism 9.5. ns: p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.Eight bar charts of YEZV P30 viral RNA in mouse tissues over 3 to 15 dpi, comparing vehicle, favipiravir, and ribavirin groups.The figure shows eight bar charts labeled Heart, Liver, Spleen, Lung, Kidney, Intestine, Brain, and Blood, each comparing YEZV P30 viral RNA levels in female C57BL/6 mice treated with vehicle, favipiravir, or ribavirin. For all tissue charts except Blood, the vertical axis is labeled logarithm base 10 RNA copies per milligram with a scale from 0 to 10 in steps of 2. The Blood chart vertical axis is labeled logarithm base 10 RNA copies per milliliter with the same numeric scale. The horizontal axis on every chart is labeled days post infection, abbreviated as dpi, and shows 3, 7, and 15. Bars for the vehicle group appear highest at 3 and 7 dpi across tissues, while bars for favipiravir and ribavirin are lower at these times and near or at the dashed horizontal limit line by 15 dpi. In the Liver chart, favipiravir bars at 3 and 7 dpi are lower than ribavirin bars. In the Spleen chart, the favipiravir bar at 7 dpi is lower than the ribavirin bar. In the remaining tissues, favipiravir and ribavirin bars at 3 and 7 dpi are similar or show small differences. At 15 dpi, most bars in all groups fall at or below the dashed limit line, with occasional slightly higher bars in Liver and Spleen. Above many grouped bars, brackets show p value symbols ns, asterisk, double asterisk, triple asterisk, or quadruple asterisk. A key identifies color coded bars as Vehicle, Favipiravir, and Ribavirin. All data are approximate. Antiviral effects on viral replication in vivo. Female C57BL/6 mice (n = 3 per group) were inoculated intraperitoneally with 1 × 104 PFU of YEZV P30 and treated orally with 300 mg/kg favipiravir or Ribavirin, initiated at 0 dpi and administered once daily for 5 days. At 3,7 and 15 dpi, mice were euthanized and blood and tissues were collected. Viral RNA copies were quantified by RT-qPCR. The dashed line indicates the LOD. The statistical analyses were performed using the two-way ANOVA test of GraphPad Prism 9.5. ns: p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Histopathological findings in antiviral-treated mice Liver and spleen samples from female mice at 5 dpi were chosen for analysis. Morphologically, the livers of antiviral-treated mice exhibited a less noticeable whitish discoloration compared with those of vehicle-treated mice (Figure S4). No significant differences were observed in the size and colour of the spleen. Histopathological analysis revealed milder inflammatory cell infiltration within the hepatic parenchyma and reduced hepatocellular necrosis in the livers of ribavirin-treated mice compared with vehicle-treated mice. Only minimal inflammatory cell infiltration and hepatocellular necrosis were observed in the livers of favipiravir-treated mice (Figure S4A). In the spleen, antiviral-treated mice displayed little to no disruption of white pulp architecture or lymphoid depletion (Figure S4B). Furthermore, while immunohistochemistry detected the YEZV antigen in the liver and spleen tissues of both favipiravir- and ribavirin-treated mice, the positive-staining areas were significantly smaller than those in vehicle-treated mice (Figure S4). Analysis of sequence variations between strains P1 and P30 Complete genome sequences of the P1 and P30 strains were amplified using semi-nested PCR and deposited in GenBank under accession numbers PZ723102–PZ723104 and PZ723105–PZ723107, respectively. Amino acid sequence comparisons revealed four differences between the P30 and P1 strains in the Nucleoprotein, all of which were located within the Nairo_nucleo region (Figure S5A). Furthermore, the P30 strain exhibited 15 amino acid substitutions in the glycoprotein precursor compared to the P1 strain: five located in the N-terminal region of the Nairovirus_M domain, one in the Hanta_G2 domain, and the remaining nine in the N-terminal region of the precursor. Additionally, the P30 strain displayed 15 amino acid substitutions in the RNA-dependent RNA-polymerase (RdRp) relative to the P1 strain, including three in the ovarian tumor (OTU) domain and two in the Bunya_RdRp domain (Figure S5A). Regarding the noncoding regions, single nucleotide substitutions were identified in the 5’ untranslated regions (UTRs) of the S, M, and L segments between the P30 and P1 strains (Figure S5B), whereas no nucleotide substitutions were detected in the 3’ UTRs (Figure S5C). Discussion In this study, a lethal YEZV strain was generated by serially passaging the parental virus in C57BL/6 mice for 30 consecutive generations. Using this adapted strain, we established an infection model in C57BL/6 mice characterized by pronounced hepatic tropism and enhanced pathogenicity specifically in female individuals. Furthermore, we demonstrated that both favipiravir and ribavirin, administered at 300 mg/kg/day, significantly suppressed viral replication and improved clinical outcomes. Since the initial identification of YEZV infection in tick-bitten patients, over sixty confirmed cases have been reported worldwide [6,10–13]. Although clinical manifestations in humans are predominantly mild, elevated serum hepatic enzyme levels are frequently observed, suggesting that YEZV is hepatotropic. This profile was further validated using the AG129 mouse model [17]. Consistently, our mouse-adapted YEZV P30 strain demonstrated pronounced hepatic tropism, reinforcing the established hepatotropic nature of this virus. In our study, female C57BL/6 mice exhibited significantly higher mortality following YEZV infection compared to males under identical challenge conditions. Although epidemiological data indicate that human males are more frequently infected with YEZV [11–13], the translational relevance of this mouse sex bias to human disease remains unclear. Notably, a similar female-biased mortality trend has been reported in CCHFV-infected young female wild-type mice, as well as in female Ifnar1 -/- and Rag1 -/- mice [23], suggesting this is a shared trait in nairovirus models. This phenomenon may lie in host immunopathology, as females generally mount more robust innate and cell-mediated immune responses driven by estrogen signalling and the double dosage of X-linked immune genes such as Tlr7 [24]. While a heightened immune response can facilitate rapid viral clearance, it can become a double-edged sword during high-titer or adapted viral infections by triggering a “cytokine storm”. Through serial passaging in C57BL/6 mice, we successfully obtained a highly virulent YEZV strain. Serial adaptation is a well-established method for selecting viral variants with increased fitness in mammalian models [23,25,26]. The efficacy of such adaptation strategies stems from the fundamental properties of RNA viruses: high mutation rates, short replication cycles, and a capacity for rapid evolutionary adaptation via point mutations, recombination, and reassortment [27]. Furthermore, RNA viruses typically exist as quasispecies, which is dynamic populations of closely related yet nonidentical variants continuously generated during replication [28]. This genetic heterogeneity enables swift adaptation to selective pressures, including host immunity, antiviral drugs, and vaccines, thereby driving immune evasion, drug resistance, and overall evolutionary fitness. The substantial accumulation of amino acid substitutions may account for the significantly enhanced pathogenicity of the P30 strain compared to the P1 strain. We identified a total of 34 amino acid substitution sites between the two viral strains, the majority of which are located within the glycoprotein precursor and RdRp (Figure S5). Notably, most mutations observed in this study occur in regions of unknown function, making it difficult to speculate on their direct functional consequences. However, three mutations were identified in the ovarian tumor (OTU) domain, which serves as a key modulator of ubiquitin- and ISG15-dependent innate immune pathways [29–31]. Although these mutations were not located within the putative polypeptide substrate-binding sites of the OTU domain, they are highly likely to modulate the host innate immune response in mice. Pinpointing the exact residue(s) responsible will require further functional validation, such as through reverse genetics approaches, to establish definitive causal links between genotype and phenotype. Broad-spectrum antivirals ribavirin and favipiravir have demonstrated therapeutic efficacy against key tick-borne RNA viruses, such as CCHFV, SFTSV, and Tick-borne encephalitis virus, across animal models or clinical settings [20,32,33]. In our lethal YEZV model, high-dose ribavirin and favipiravir both conferred protection regardless of treatment timing. At low doses, however, ribavirin initiated at 3 dpi yielded significantly lower survival than favipiravir (Figure 4). These findings indicate that effective YEZV management requires adequate dosing and timely administration. While favipiravir demonstrates superior antiviral efficacy, ribavirin remains a viable alternative, particularly in resource-limited settings due to its lower cost and wider availability. In summary, we generated a lethal, mouse-adapted YEZV strain after 30 serial passages in C57BL/6 mice. This model enabled robust characterization of lethal infection and confirmed significant in vivo antiviral efficacy for both favipiravir and ribavirin, providing a validated platform and critical data for studying YEZV pathogenesis and developing antiviral therapeutics. Ethics statement and biosafety All animal experiments were approved by the Animal Care and Use Committee of the Changchun Veterinary Research Institute (Approval No.: AMMS-11-2020-026). Procedures involving YEZV-infected mice were conducted in a designated containment area within an Animal Biosafety Level 2 (ABSL-2) facility, as described in a previous YEZV mouse infection model study [17]. The studies were conducted in accordance with the local legislation and institutional requirements. Mice were handled humanely, anesthetized with an intravenous bolus of ethyl carbamate (100 mg/mL) at a dose of 1000 mg/kg based on body weight, and euthanized by carbon dioxide overdose. All procedures complied with the Animal Ethics Procedures and Guidelines of the People’s Republic of China. Supplementary Material Supplemental material.docx Supplemental Data.xlsx